| Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ... European urology 75 (4), 667-675, 2019 | 169 | 2019 |
| Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ... Clinical cancer research 23 (21), 6487-6497, 2017 | 146 | 2017 |
| Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer G Vandekerkhove, JM Lavoie, M Annala, AJ Murtha, N Sundahl, S Walz, ... Nature Communications 12 (1), 184, 2021 | 100 | 2021 |
| Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer C Herberts, M Annala, J Sipola, SWS Ng, XE Chen, A Nurminen, ... Nature 608 (7921), 199-208, 2022 | 88 | 2022 |
| BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression E Warner, C Herberts, S Fu, S Yip, A Wong, G Wang, E Ritch, AJ Murtha, ... Clinical Cancer Research 27 (6), 1650-1662, 2021 | 67 | 2021 |
| Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ... Clinical Cancer Research 26 (5), 1114-1125, 2020 | 66 | 2020 |
| Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ... European urology 78 (6), 834-844, 2020 | 64 | 2020 |
| Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma ECP Chedgy, G Vandekerkhove, C Herberts, M Annala, AJ Donoghue, ... The Journal of pathology 246 (2), 244-253, 2018 | 43 | 2018 |
| Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA E Ritch, AW Wyatt Urologic Oncology: Seminars and Original Investigations 36 (8), 380-384, 2018 | 16 | 2018 |
| Genomic features of lung-recurrent hormone-sensitive prostate cancer NM Fonseca, K Van der Eecken, C Herberts, S Verbeke, SWS Ng, ... JCO precision oncology 6, e2100543, 2022 | 9 | 2022 |
| Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy JVW Bacon, DC Müller, E Ritch, M Annala, SG Dugas, C Herberts, ... European Urology Oncology 5 (6), 677-686, 2022 | 8 | 2022 |
| Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping EW Warner, K Van der Eecken, AJ Murtha, EM Kwan, C Herberts, J Sipola, ... Nature Cancer, 1-17, 2024 | 5 | 2024 |
| A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes EJ Ritch, C Herberts, EW Warner, SWS Ng, EM Kwan, JVW Bacon, ... NPJ Precision Oncology 7 (1), 27, 2023 | 5 | 2023 |
| Enhancing knowledge discovery from cancer genomics data with Galaxy MA Albuquerque, BM Grande, EJ Ritch, P Pararajalingam, S Jessa, ... Giga Science 6 (5), gix015, 2017 | 5 | 2017 |
| Genome-wide CRISPR screen reveals SLFN11 as a potent mediator of cisplatin sensitivity in muscle-invasive bladder cancer G Kumar, E Ritch, HZ Oo, CK Wang, D Tortora, D Thaper, I Moskalev, ... Urologic Oncology: Seminars and Original Investigations 38 (12), 905, 2020 | 2 | 2020 |
| A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer D Tortora, ME Roberts, G Kumar, SS Kotapalli, E Ritch, JM Scurll, ... Iscience 26 (5), 2023 | 1 | 2023 |
| Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer E Warner, K Van der Eecken, AJ Murtha, EM Kwan, SW Ng, XE Chen, ... Cancer Research 82 (12_Supplement), 41-41, 2022 | 1 | 2022 |
| Early Identification of Refractory/Relapsed Diffuse Large B Cell Lymphoma with Serial Ctdna Sampling RN Rys, E Ritch, C Rushton, A Ahmed, E Brailovski, C Steidl, DW Scott, ... Blood 142, 2996, 2023 | | 2023 |
| Abstract IA006: Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer AW Wyatt, AJ Murtha, E Warner, K Van der Eecken, EM Kwan, C Herberts, ... Cancer Research 83 (11_Supplement), IA006-IA006, 2023 | | 2023 |
| Clonal architecture and evolution of treatment-resistant prostate cancer via deep whole-genome ctDNA sequencing C Herberts, M Annala, J Sipola, SW Ng, XE Chen, A Nurminen, ... Cancer Research 82 (12_Supplement), 3625-3625, 2022 | | 2022 |
